Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space

由 Sartor, A Oliver
出版 2011

Germline BLM mutations and metastatic prostate cancer

由 Ledet, Elisa M., Antonarakis, Emmanuel S., Isaacs, William B., Lotan, Tamara L., Pritchard, Colin, Sartor, A. Oliver
發表在 Prostate (2019)

A Medical Pearl Harbor: Pandemic Uncovers Societal Fissures and Leadership Breaches

由 Chabner, Bruce A., Bates, Susan E., Fojo, Antonio Tito, Murphy, Ann, Sartor, A. Oliver, Murphy, Martin J.
發表在 Oncologist (2021)

Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease

由 Bennett, Charles L., Qureshi, Zaina P., Sartor, A. Oliver, Norris, LeAnn B., Murday, Alanna, Xirasagar, Sudha, Thomsen, Henrik S.
出版 2012

Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer

由 Moses, Marcus, Koksal, Ulkuhan, Ledet, Elisa, Manogue, Charlotte, Cotogno, Patrick, Lewis, Brian, Layton, Jodi, Sartor, A. Oliver, Barata, Pedro
發表在 Oncotarget (2020)

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

由 Armstrong, Andrew J., Eisenberger, Mario A., Halabi, Susan, Oudard, Stephane, Nanus, David M., Petrylak, Daniel P., Sartor, A. Oliver, Scher, Howard I.
出版 2011

Cytokine genetic polymorphisms and prostate cancer aggressiveness

由 Zabaleta, Jovanny, Su, L. Joseph, Lin, Hui-Yi, Sierra, Rosa A., Hall, M. Craig, Sartor, A. Oliver, Clark, Peter E., Hu, Jennifer J., Ochoa, Augusto C.
出版 2009

Antiandrogen Withdrawal in Castrate-refractory Prostate Cancer: A Southwest Oncology Group Trial (SWOG 9426)

由 Sartor, A. Oliver, Tangen, Catherine M., Hussain, Maha H. A., Eisenberger, Mario A., Parab, Minoti, Fontana, Joseph A., Chapman, Robert A., Mills, Glenn M., Raghavan, Derek, Crawford, E. David
出版 2008

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

由 Beer, Tomasz M, Vogelzang, Nicholas, Bartůňková, Jiřina, Miller, Kurt, Oh, William, Oudard, Stephane, Pandha, Hardev, Sartor, A Oliver, Špíšek, Radek, Toole, Timothy O, Borgstein, Niels G, Gerritsen, Winald R
發表在 J Immunother Cancer (2015)

CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion

由 Liu, Sen, Liu, Fengli, Zhang, Bing, Yan, Peng, Rowan, Brian G., Abdel-Mageed, Asim B., Steele, Chad, Jazwinski, S. Michal, Moroz, Krzysztof, Norton, Elizabeth B., Wang, Alun, Myers, Leann, Sartor, A. Oliver, Zhang, Qiuyang
發表在 Prostate (2020)

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Ra...

由 Terrisse, Safae, Karamouza, Eleni, Parker, Chris C., Sartor, A. Oliver, James, Nicholas D., Pirrie, Sarah, Collette, Laurence, Tombal, Bertrand F., Chahoud, Jad, Smeland, Sigbjørn, Erikstein, Bjørn, Pignon, Jean-Pierre, Fizazi, Karim, Le Teuff, Gwénaël
發表在 JAMA Oncol (2020)

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer

由 Pomerantz, Mark M., Spisák, Sandor, Jia, Li, Cronin, Angel M., Csabai, Istvan, Ledet, Elisa, Sartor, A. Oliver, Rainville, Irene, O’Connor, Edward, Herbert, Zachary T., Szállási, Zoltan, Oh, William K., Kantoff, Philip W., Garber, Judy E., Schrag, Deborah, Kibel, Adam S., Freedman, Matthew L.
發表在 Cancer (2017)

A Phase III trial of 2 Years of Androgen Suppression (AS) and Radiation Therapy (RT) with or without Adjuvant Chemotherapy (CT) for High-Risk Prostate Cancer: Final Results of Radi...

由 Rosenthal, Seth A., Hunt, Daniel, Sartor, A. Oliver, Pienta, Kenneth J., Gomella, Leonard, Grignon, David, Rajan, Raghu, Kerlin, Kevin J., Jones, Christopher U., Dobelbower, Michael, Shipley, William U., Zeitzer, Kenneth, Hamstra, Daniel A., Donavanik, Viroon, Rotman, Marvin, Hartford, Alan C., Michalski, Jeffrey, Seider, Michael, Kim, Harold, Kuban, Deborah A., Moughan, Jennifer, Sandler, Howard
發表在 Int J Radiat Oncol Biol Phys (2015)

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

由 Smith, Matthew R., Sweeney, Christopher J., Corn, Paul G., Rathkopf, Dana E., Smith, David C., Hussain, Maha, George, Daniel J., Higano, Celestia S., Harzstark, Andrea L., Sartor, A. Oliver, Vogelzang, Nicholas J., Gordon, Michael S., de Bono, Johann S., Haas, Naomi B., Logothetis, Christopher J., Elfiky, Aymen, Scheffold, Christian, Laird, A. Douglas, Schimmoller, Frauke, Basch, Ethan M., Scher, Howard I.
發表在 J Clin Oncol (2014)

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

由 Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.
發表在 Cancer (2019)